21 Jan 2022 , 01:17 PM
Laurus Labs Ltd. has signed an agreement with MPP (Medicine Patient Pool) for the manufacturing of the oral COVID-19 antiviral medication Molnupiravir.
The company is happy to sign an agreement to manufacture the oral Covid-19 antiviral medication, being an urgent need of the hour, this is one of the most crucial steps towards fighting the pandemic and the company is happy to be contributing to the mission, stated the company in its regulatory filing.
Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs.
The company also develops and manufactures oral solid formulations, provides contract research and manufacturing services (CRAMS) to Global pharma companies, and produces specialty ingredients for nutraceuticals, dietary supplements, and cosmeceuticals. The company is highly passionate about advanced chemistry skills.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
